Stone House Investment Management’s BeOne Medicines Ltd ONC Stock Holding History

Stone House Investment Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$855	Buy	+3	New	+$884	﹤0.01%	914

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stone House Investment Management's ONC Position: Q2 2026 in Review

Stone House Investment Management opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 3 shares worth $855. The stake represents ﹤0.01% of the portfolio and ranks #914 among its holdings.

282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Stone House Investment Management held 3 shares of BeOne Medicines Ltd worth $855 as of Q2 2026.
BeOne Medicines Ltd was a new Stone House Investment Management position in Q2 2026.
BeOne Medicines Ltd made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #914 holding.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.